...
首页> 外文期刊>BMC Pregnancy and Childbirth >Establishment of a risk assessment tool for pregnancy-associated venous thromboembolism and its clinical application: protocol for a prospective observational study in Beijing
【24h】

Establishment of a risk assessment tool for pregnancy-associated venous thromboembolism and its clinical application: protocol for a prospective observational study in Beijing

机译:妊娠相关性静脉血栓栓塞风险评估工具的建立及其临床应用:北京前瞻性观察研究方案

获取原文
           

摘要

The risk of venous thromboembolism (VTE) during pregnancy and puerperal periods is significantly higher than during the non-pregnant period and is one of the major causes of maternal mortality. Developed countries have promulgated guidelines for risk assessment and prevention of maternal VTE, and standardized management has led to a significant reduction in maternal mortality. However, there is a paucity of relevant research related to pregnancy and puerperal VTE in China. We will perform a prospective cohort study and recruit 13,000 pregnant women from 2018 to 2020 in Beijing, China. VTE risk assessment will be conducted using the Royal College of Obstetricians and Gynaecologists (RCOG) pregnancy and puerperal VTE risk-assessment-scoring tool during early and late pregnancy, as well as during the puerperal period. Venous ultrasonography of lower extremities, routine blood tests, and coagulation parameters will be examined. These VTE risk assessments will be performed again if patients have VTE-related symptoms during their pregnancies, or if any of the following occur: (1) patients are hospitalized over 7 days due to any pregnancy complications; (2) patients are placed under strict bed rest for ≥ 3 days to prevent miscarriage. For patients with a confirmed diagnosis of VTE, treatment and follow-up plans will be decided jointly by the obstetricians, vascular surgeons, and pulmonologists. All patients in the study will be followed up by dedicated healthcare providers for up to 42?days postpartum. Statistical analyses will be performed to test the feasibility of the RCOG scoring tool for the Chinese population. The RCOG scoring tool will then be revised based upon the characteristics of the Chinese population, and the revised assessment scoring tool will then be tested in the cohort to evaluate its efficacy. Finally, a pregnancy and puerperal VTE risk-assessment tool will be proposed based on our study results. This study will establish a preliminary VTE risk-assessment tool that is applicable to pregnant and puerperal women in China and provide guidelines for further thrombophylactic interventions. Furthermore, we wish to draw increased attention to pregnancy-associated VTE to reduce VTE-related mortality. Chi CTR1800015848 (04/24/2018).
机译:妊娠和产褥期静脉血栓栓塞(VTE)的风险明显高于非妊娠期,这是孕产妇死亡的主要原因之一。发达国家已经颁布了风险评估和预防孕产妇VTE的准则,标准化管理已大大降低了孕产妇死亡率。但是,在中国,与妊娠和产后VTE相关的研究很少。我们将进行一项前瞻性队列研究,并于2018年至2020年在中国北京招募13,000名孕妇。 VTE风险评估将使用皇家妇产科学院(RCOG)妊娠和产后VTE风险评估评分工具在妊娠早期和晚期以及产褥期进行。将检查下肢的静脉超声检查,常规血液检查和凝血参数。如果患者在怀孕期间出现与VTE相关的症状,或者发生以下任何一种情况,将再次进行这些VTE风险评估:(1)患者由于任何妊娠并发症而住院了7天; (2)患者应严格卧床休息≥3天,以防止流产。对于确诊为VTE的患者,产科医生,血管外科医师和肺科医师将共同决定治疗和后续计划。研究中的所有患者将在产后长达42天的时间里由专门的医疗保健人员进行随访。将进行统计分析,以测试RCOG评分工具对中国人口的可行性。然后,将根据中国人口的特征对RCOG评分工具进行修订,并在队列中对修订后的评估评分工具进行测试,以评估其有效性。最后,根据我们的研究结果,将提出妊娠和产后VTE风险评估工具。这项研究将建立适用于中国孕妇和产妇的初步VTE风险评估工具,并为进一步的血栓预防干预措施提供指导。此外,我们希望引起人们对与妊娠相关的VTE的更多关注,以降低与VTE相关的死亡率。 Chi CTR1800015848(04/24/2018)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号